Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new bisintercalating anthracycline with picomolar DNA binding affinity.

José Portugal1, Derek J Cashman, John O Trent

  • 1Instituto de Biologia Molecular de Barcelona, CSIC, Parc Científic de Barcelona, Josep Samitier, 1-5, E-08028, Barcelona, Spain. jpmbmc@ibmb.csic.es

Journal of Medicinal Chemistry
|December 22, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Protein Drugs: A 2025 Update.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis.

International journal of biological macromolecules·2026
Same author

Insulin-independent glucose uptake in skeletal muscle by coupled SGLT and Na,K-ATPase transport.

bioRxiv : the preprint server for biology·2026
Same author

Demographics, methods of use, and perceived benefits among patients with cancer who use cannabis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

A c-Cbl/Cbl-b antagonist inhibits EGFR ubiquitylation and sustains EGFR phosphorylation to enhance corneal re-epithelialization.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Polyphosphate-mediated heavy metal sequestration in non-genetically modified bacteria: mechanisms and biotechnological prospects.

Chemosphere·2026

A novel bisintercalating anthracycline, WP762, exhibits ultra-tight DNA binding due to its unique linker. This enhanced DNA binding translates to increased cytotoxicity in cancer cell lines compared to related compounds.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Biophysics

Background:

  • Anthracyclines are a critical class of anticancer drugs.
  • Developing novel anthracycline analogs with improved DNA binding and efficacy is an ongoing research area.
  • Bis-anthracyclines offer potential for enhanced DNA interaction and therapeutic outcomes.

Purpose of the Study:

  • To design and synthesize a new bisintercalating anthracycline, WP762, utilizing daunorubicin monomers.
  • To characterize the DNA binding properties and thermodynamic parameters of WP762.
  • To evaluate the cytotoxicity and cellular effects of WP762 in comparison to existing anthracyclines.

Main Methods:

  • Chemical synthesis of the bisintercalating anthracycline WP762.
  • Differential scanning calorimetry and UV melting experiments for DNA binding analysis.

Related Experiment Videos

  • Comparative molecular modeling to elucidate linker effects on DNA interaction.
  • Cytotoxicity assays in Jurkat T lymphocytes and cell-cycle analysis.

    • Main Results:

    • WP762 demonstrated ultra-tight binding to DNA with a binding constant of 7.3 x 10^12 M^-1.
    • The binding free energy was highly favorable (-17.3 kcal mol^-1), driven by enthalpic contributions.
    • Molecular modeling indicated optimal positioning of the m-xylenyl linker in the DNA minor groove.
    • WP762 exhibited greater cytotoxicity in Jurkat T lymphocytes compared to WP631.

    Conclusions:

    • The novel bisintercalating anthracycline WP762 possesses exceptionally strong DNA binding affinity.
    • The m-xylenyl linker contributes to enhanced DNA groove binding and overall drug efficacy.
    • WP762 represents a promising new anthracycline derivative with potential for increased anticancer activity.